1-5 of 5
Marc E Buyse, ScD
Close
Sort by
Journal Articles

Multicentre, Open Label, Randomized Phase III Study of Cpi-613 ® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Timothy S. Pardee, MD PhD, Sanjeev Luther, MBA, Marc E. Buyse, ScD, Bayard L Powell, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2658.
https://doi.org/10.1182/blood-2019-129377
Published: 2019
Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Hagop M. Kantarjian, MD, Kebede H. Begna, MD, Jessica K. Altman, MD, Stuart L. Goldberg, MD, Mikkael A. Sekeres, MD MS, Stephen A Strickland, Stephen E. Rubenstein, MD, Martha L. Arellano, MD, David F. Claxton, Maria R. Baer, MD, Marc Gautier, MD, Ellin Berman, MD, Karen Seiter, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Selina Luger, MD FRCPC, Aleksandra Butrym, Gianluca Gaidano, MD PhD, Xavier Thomas, MD, Pau Montesinos, MD PhD, David A. Rizzieri, MD, Donald P. Quick, MD, Edward Agura, MD, Parameswaran Venugopal, MD, Janakiraman Subramanian, MD, Lori J. Maness, MD, Daniel-Eric Robert, MD, Yosr Hicheri, Tapan Kadia, MD, Farhad Ravandi, MBBS, Marc E. Buyse, ScD, Judy Chiao, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 891.
https://doi.org/10.1182/blood.V130.Suppl_1.891.891
Published: 2017
Journal Articles

Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia

Richard F. Schlenk, MD, Hartmut Döhner, Prof. MD, Konstanze Döhner, MD, Arnold Ganser, Michael Heuser, MD, Axel Benner, Marc E. Buyse, ScD, Tomasz Burzykowski, PhD
Journal: Blood
Blood (2015) 126 (23): 3744.
https://doi.org/10.1182/blood.V126.23.3744.3744
Published: 2015
Journal Articles

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

Pierre Squifflet, Master of Science in Statistics, Stefan Michiels, David S. Siegel, MD, PhD, Ravi Vij, MD, Sunhee Ro, Ph.D., Marc E Buyse, ScD
Journal: Blood
Blood (2011) 118 (21): 1877.
https://doi.org/10.1182/blood.V118.21.1877.1877
Published: 2011
Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Assessment of Consistency and Robustness of Treatment Benefit for Patients in First Complete Remission.

Marc E Buyse, ScD, Pierre Squifflet, MSc, Jacob M Rowe, MD, John K Whisnant, MD, Dileep Bhagwat, PhD, MBA, Stephane E Allard, MD, Kristoffer Hellstrand, MD, PhD, Mats L Brune, MD
Journal: Blood
Blood (2008) 112 (11): 1948.
https://doi.org/10.1182/blood.V112.11.1948.1948
Published: 2008